MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen Total Assets 2011-2026 | OPGN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.86 M | 1.88 M | 25.8 M | 71.7 M | 49.8 M | 10.4 M | 8.95 M | 6.62 M | 8.98 M | 13.8 M | 2.65 M | 3.16 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.7 M | 1.88 M | 17.8 M |
Quarterly Total Assets OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.6 M | 13.2 M | 9.42 M | 9.86 M | 5.47 M | 2.87 M | - | 1.88 M | 18.1 M | 22.4 M | 26.5 M | 25.8 M | 33 M | 48.8 M | 64.3 M | 71.7 M | 62.3 M | 68.6 M | 75.2 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 8.95 M | 8.95 M | 8.95 M | 8.95 M | 6.62 M | 6.62 M | 6.62 M | 6.62 M | 8.98 M | 8.98 M | 8.98 M | 8.98 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 2.65 M | 2.65 M | 2.65 M | 2.65 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 75.2 M | 1.88 M | 21.2 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
10.7 B | $ 114.78 | -0.61 % | $ 34.9 B |  USA |
|
Biodesix
BDSX
|
97.2 M | $ 15.7 | 4.18 % | $ 2.04 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.15 | -0.83 % | $ 4.94 M | USA |
 |
BioNano Genomics
BNGO
|
73.6 M | $ 1.16 | -3.33 % | $ 6.32 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.33 | 0.8 % | $ 176 M |  China |
 |
CareDx, Inc
CDNA
|
413 M | $ 18.12 | -1.04 % | $ 966 M | USA |
 |
Celcuity
CELC
|
467 M | $ 114.33 | 1.5 % | $ 5.35 B | USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 166.88 | -4.03 % | $ 8.27 B | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 25.0 | 0.64 % | $ 694 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M |  Israel |
 |
Danaher Corporation
DHR
|
83.5 B | $ 191.23 | 0.06 % | $ 136 B | USA |
 |
DexCom
DXCM
|
6.34 B | $ 63.01 | 1.26 % | $ 24.6 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 16.56 | -1.55 % | $ 501 M | USA |
 |
Guardant Health
GH
|
2.01 B | $ 90.84 | -3.19 % | $ 11.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 111.1 | -2.71 % | $ 9.16 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 1.92 | -1.92 % | $ 8.49 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 126.95 | -0.34 % | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 169.58 | -2.12 % | $ 29.2 B | USA |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 274.35 | 0.23 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 75.67 | -0.57 % | $ 5.11 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 494.14 | -0.84 % | $ 14.3 B | USA |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 256.28 | -0.29 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.76 | 0.11 % | $ 441 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
ENDRA Life Sciences
NDRA
|
3.85 M | $ 4.57 | -2.46 % | $ 3.6 M | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 7.98 | -0.25 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.51 | 1.01 % | $ 2.06 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 17.43 | 1.6 % | $ 390 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 204.77 | -1.54 % | $ 20.2 B | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.41 | 5.05 % | $ 423 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 27.02 | -0.33 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
21.3 M | $ 26.84 | 5.67 % | $ 43.1 M | USA |
 |
Personalis
PSNL
|
270 M | $ 6.64 | 0.84 % | $ 393 M | USA |
 |
RadNet
RDNT
|
3.76 B | $ 55.13 | 0.62 % | $ 4.15 B | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |